Business Context and Reporting Period
This Form 8-K is filed by Oncobiologics, Inc. (noting the metadata reference to "Outlook Therapeutics" appears to be a discrepancy, as the filing text identifies the registrant as Oncobiologics, Inc.) on October 2, 2017. The report addresses a corporate governance issue regarding compliance with Nasdaq listing standards rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a listing status notification and contains no financial statements or operational metrics.
Material Changes
The material change reported is a regulatory notification received on October 2, 2017, from Nasdaq. The Company was notified of non-compliance with Nasdaq Marketplace Rule 5620(a) because it had not held an annual meeting of shareholders within twelve months of its fiscal year end. This notification has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market.
Outlook, Management Commentary, and Risks
- Compliance Plan: The Company has 45 calendar days to submit a plan to regain compliance. If accepted, Nasdaq may grant an exception of up to 180 days (until March 29, 2018).
- Remediation Action: The Company filed a definitive proxy statement on September 29, 2017, for an Annual Meeting of Stockholders scheduled for October 26, 2017.
- Management Expectation: Management expects that upon completion of the October 26 meeting, the Company will be in compliance with Rule 5620(a).
- Risks: There is no assurance that the Company will successfully regain compliance or maintain its listing. If the plan is not accepted, the Company may request a hearing to suspend delisting determinations.
Investor Verification Checklist
- Verify the outcome of the Annual Meeting of Stockholders held on October 26, 2017.
- Confirm whether Nasdaq accepted the Company's plan to regain compliance or if a hearing was required.
- Monitor subsequent filings for any updates on the Company's listing status on the Nasdaq Global Market.
- Clarify the corporate identity discrepancy between the metadata ("Outlook Therapeutics") and the filing text ("Oncobiologics, Inc.").